| Program | Target/MOA | Indication | Research | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|
| Efzofitimod | NRP2 agonist | Pulmonary Sarcoidosis(1) |
|
||||
| SSc-ILD(2) |
|
||||||
| Other ILD (CTD-ILD; CHP)(3) |
|
||||||
| ATYR2810 | NRP2/VEGF antagonist | Solid Tumors |
|
||||
| AARS | FGFR4 modulator | Fibrosis |
|
||||
| DARS | LTBP1 modulator | Fibrosis |
|
||||
| NRP2 mAbs | NRP2/CCR7 antagonist | Inflammation |
|
||||
| NRP2/SEMA3F antagonist | Inflammation |
|
|||||
| Program/ Target |
Indication | Phase |
|---|---|---|
| Efzofitimod (ATYR1923) NRP2 agonist |
Pulmonary Sarcoidosis(1) | Phase 3 |
| SSc-ILD(2) | Phase 1 | |
| Other ILD (CTD-ILD; CHP)(3) | Phase 1 | |
| ATYR2810 NRP2/VEGF antagonist |
Solid Tumors | Phase 1 |
| AARS FGFR4 modulator |
Fibrosis | Research |
| DARS LTBP1 modulator |
Fibrosis | Research |
| NRP2 mAbs NRP2/CCR7 antagonist |
Inflammation | Research |
| NRP2 mAbs NRP2/SEMA3F antagonist |
Inflammation | Research |
(1) In partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILD in Japan
(2) SSc-ILD: Scleroderma-related ILD
(3) CTD-ILD: Connective Tissue Disease-ILD; CHP: Chronic Hypersensitivity Pneumonitis